↓ Skip to main content

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

Overview of attention for article published in Molecular Cancer, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)

Mentioned by

news
1 news outlet
twitter
2 tweeters
reddit
1 Redditor

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
126 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Published in
Molecular Cancer, February 2018
DOI 10.1186/s12943-018-0810-4
Pubmed ID
Authors

Brandon Golding, Anita Luu, Robert Jones, Alicia M. Viloria-Petit

Abstract

Lung cancer is the leading cause of death by cancer in North America. A decade ago, genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase were identified in a subset of non-small cell lung carcinoma (NSCLC) patients. Soon after, crizotinib, a small molecule ATP-competitive ALK inhibitor was proven to be more effective than chemotherapy in ALK-positive NSCLC patients. Crizotinib and two other ATP-competitive ALK inhibitors, ceritinib and alectinib, are approved for use as a first-line therapy in these patients, where ALK rearrangement is currently diagnosed by immunohistochemistry and in situ hybridization. The clinical success of these three ALK inhibitors has led to the development of next-generation ALK inhibitors with even greater potency and selectivity. However, patients inevitably develop resistance to ALK inhibitors leading to tumor relapse that commonly manifests in the form of brain metastasis. Several new approaches aim to overcome the various mechanisms of resistance that develop in ALK-positive NSCLC including the knowledge-based alternate and successive use of different ALK inhibitors, as well as combined therapies targeting ALK plus alternative signaling pathways. Key issues to resolve for the optimal implementation of established and emerging treatment modalities for ALK-rearranged NSCLC therapy include the high cost of the targeted inhibitors and the potential of exacerbated toxicities with combination therapies.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 126 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 22 17%
Researcher 17 13%
Student > Master 15 12%
Student > Ph. D. Student 10 8%
Other 9 7%
Other 14 11%
Unknown 39 31%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 31 25%
Medicine and Dentistry 26 21%
Pharmacology, Toxicology and Pharmaceutical Science 8 6%
Chemistry 4 3%
Agricultural and Biological Sciences 4 3%
Other 14 11%
Unknown 39 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2021.
All research outputs
#3,557,621
of 19,846,165 outputs
Outputs from Molecular Cancer
#173
of 1,490 outputs
Outputs of similar age
#73,037
of 290,256 outputs
Outputs of similar age from Molecular Cancer
#1
of 1 outputs
Altmetric has tracked 19,846,165 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,490 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,256 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them